Loading…
Barriers and facilitators to viral hepatitis testing in Uzbekistan: scoping qualitative study among key stakeholders, healthcare workers, and the general population
In the World Health Organization European Region, an estimated 14 million people live with a chronic hepatitis B virus infection (HBV), and 12 million are affected by a hepatitis C virus infection (HCV). Uzbekistan bears a major burden of HBV and has one of the highest HCV prevalence in the region....
Saved in:
Published in: | BMC public health 2024-06, Vol.24 (1), p.1482-1482, Article 1482 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c445t-70010c6d21ab326fc502070d7297a6d28b16d47b938c69b7b2ffbfd566a75da63 |
container_end_page | 1482 |
container_issue | 1 |
container_start_page | 1482 |
container_title | BMC public health |
container_volume | 24 |
creator | Mazhnaya, Alyona Geurts, Brogan Brigida, Krestina Bakieva, Shokhista Sadirova, Shakhlo Witzigmann, Annika Musabaev, Erkin Brandl, Michael Weishaar, Heide Dudareva, Sandra Bcheraoui, Charbel El |
description | In the World Health Organization European Region, an estimated 14 million people live with a chronic hepatitis B virus infection (HBV), and 12 million are affected by a hepatitis C virus infection (HCV). Uzbekistan bears a major burden of HBV and has one of the highest HCV prevalence in the region. Following a presidential decree in May 2022, significant funds were allocated to the viral hepatitis (VH) elimination program in Uzbekistan. The program expands VH testing to reach 500,000 people annually during 2022-2025 as part of the VH elimination strategy that includes the provision of free testing and affordable treatment. Exploring the existing barriers and facilitators to VH testing is pivotal for informing these interventions.
This study uses a cross-sectional qualitative design to identify and explore the barriers and facilitators to VH testing among the general population in Uzbekistan. We collected data during October-November 2022 through semi-structured interviews with 12 key informants (KIs) and 7 focus group discussions with two target populations: the general population and healthcare workers (HCW) in Tashkent, Uzbekistan.
Following the capability-opportunity-motivation-behavior model (COM-B model) as a framework for the analysis, we identified major capability barriers to VH testing primarily linked to low health literacy and limited knowledge about VH types, symptoms, transmission, testing and treatment. Physical opportunity barriers included the time and financial costs associated with testing, diagnostics, and treatment. Sociocultural opportunity barriers involved anticipated negative reactions and stigmatization, particularly affecting women. Motivational barriers included a reluctance to be tested when asymptomatic and a general fear of receiving positive test results. The involvement of healthcare workers in promoting VH awareness and motivating the general population emerged as a facilitator.
A multi-pronged approach is recommended to achieve VH testing goals among the general population, focusing on raising awareness and health literacy and creating an enabling environment that ensures easy accessibility and minimizing VH testing-associated costs. |
doi_str_mv | 10.1186/s12889-024-18953-5 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_fcf877044aca4049891bb5ff7a26f89b</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A796233744</galeid><doaj_id>oai_doaj_org_article_fcf877044aca4049891bb5ff7a26f89b</doaj_id><sourcerecordid>A796233744</sourcerecordid><originalsourceid>FETCH-LOGICAL-c445t-70010c6d21ab326fc502070d7297a6d28b16d47b938c69b7b2ffbfd566a75da63</originalsourceid><addsrcrecordid>eNptks9u1DAQxiMEoqXwAhxQJC4cSLEdJ3a4oFLxp1IlLvRsTRx717vZOLWdRcvz8KBMdkvpIpRDki_z_SYz_rLsJSXnlMr6XaRMyqYgjBdUNlVZVI-yU8oFLRiv5OMHzyfZsxhXhFAhK_Y0OymlLNFcnWa_PkIIzoSYw9DlFrTrXYLkUUg-37oAfb40IySXHEomJjcscjfkNz9bs3YxwfA-j9qPs3w7wd7ttiaPaep2OWw86muzw3dYm6XvO-z1FpHQp6WGYPIfPqz32vwDaWnyhRnM3Hb049QjzA_PsycW-mhe3N3PspvPn75ffi2uv325ury4LjTnVSoEDkh03TEKbclqqyvCiCCdYI0AlGVL646LtimlrptWtMza1nZVXYOoOqjLs-zqwO08rNQY3AbCTnlwai_4sFAQktO9UVZbKQThHDRwwhvZ0LatrBWAjWXTIuvDgTVO7cZ02gwJhzqCHn8Z3FIt_FZRSvHESoaEN3eE4G8n3LzauKhN38Ng_BRVSWpeiaYhHEtf_1O68lMYcFdzVS3x1IX4W7UAnMAN1mNjPUPVhWhqVpaCz6zz_1Th1ZmN034w1qF-ZGAHgw4-xmDs_ZCUqDmo6hBUhUFV-6CqCk2vHq7n3vInmeVvJOPmuA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3066885277</pqid></control><display><type>article</type><title>Barriers and facilitators to viral hepatitis testing in Uzbekistan: scoping qualitative study among key stakeholders, healthcare workers, and the general population</title><source>PMC (PubMed Central)</source><source>Publicly Available Content (ProQuest)</source><source>Coronavirus Research Database</source><creator>Mazhnaya, Alyona ; Geurts, Brogan ; Brigida, Krestina ; Bakieva, Shokhista ; Sadirova, Shakhlo ; Witzigmann, Annika ; Musabaev, Erkin ; Brandl, Michael ; Weishaar, Heide ; Dudareva, Sandra ; Bcheraoui, Charbel El</creator><creatorcontrib>Mazhnaya, Alyona ; Geurts, Brogan ; Brigida, Krestina ; Bakieva, Shokhista ; Sadirova, Shakhlo ; Witzigmann, Annika ; Musabaev, Erkin ; Brandl, Michael ; Weishaar, Heide ; Dudareva, Sandra ; Bcheraoui, Charbel El</creatorcontrib><description>In the World Health Organization European Region, an estimated 14 million people live with a chronic hepatitis B virus infection (HBV), and 12 million are affected by a hepatitis C virus infection (HCV). Uzbekistan bears a major burden of HBV and has one of the highest HCV prevalence in the region. Following a presidential decree in May 2022, significant funds were allocated to the viral hepatitis (VH) elimination program in Uzbekistan. The program expands VH testing to reach 500,000 people annually during 2022-2025 as part of the VH elimination strategy that includes the provision of free testing and affordable treatment. Exploring the existing barriers and facilitators to VH testing is pivotal for informing these interventions.
This study uses a cross-sectional qualitative design to identify and explore the barriers and facilitators to VH testing among the general population in Uzbekistan. We collected data during October-November 2022 through semi-structured interviews with 12 key informants (KIs) and 7 focus group discussions with two target populations: the general population and healthcare workers (HCW) in Tashkent, Uzbekistan.
Following the capability-opportunity-motivation-behavior model (COM-B model) as a framework for the analysis, we identified major capability barriers to VH testing primarily linked to low health literacy and limited knowledge about VH types, symptoms, transmission, testing and treatment. Physical opportunity barriers included the time and financial costs associated with testing, diagnostics, and treatment. Sociocultural opportunity barriers involved anticipated negative reactions and stigmatization, particularly affecting women. Motivational barriers included a reluctance to be tested when asymptomatic and a general fear of receiving positive test results. The involvement of healthcare workers in promoting VH awareness and motivating the general population emerged as a facilitator.
A multi-pronged approach is recommended to achieve VH testing goals among the general population, focusing on raising awareness and health literacy and creating an enabling environment that ensures easy accessibility and minimizing VH testing-associated costs.</description><identifier>ISSN: 1471-2458</identifier><identifier>EISSN: 1471-2458</identifier><identifier>DOI: 10.1186/s12889-024-18953-5</identifier><identifier>PMID: 38831285</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adult ; Barriers and facilitators ; Behavior change ; Care and treatment ; Central Asia ; Chronic illnesses ; Chronic infection ; Cross-Sectional Studies ; Diagnosis ; Disease transmission ; Elimination ; Female ; Females ; Focus Groups ; Health behavior ; Health care ; Health Personnel - psychology ; Health Services Accessibility ; Hepatitis ; Hepatitis B ; Hepatitis C ; Hepatitis testing ; Hepatitis, Viral ; Hepatitis, Viral, Human - diagnosis ; Hepatitis, Viral, Human - epidemiology ; Hepatitis, Viral, Human - prevention & control ; Humans ; Immunization ; Infections ; Interviews as Topic ; Literacy ; Male ; Mass Screening ; Medical personnel ; Middle Aged ; Pilot projects ; Population ; Practice ; Prevention ; Primary care ; Public health ; Qualitative Research ; Risk factors ; Stakeholder Participation ; Uzbekistan</subject><ispartof>BMC public health, 2024-06, Vol.24 (1), p.1482-1482, Article 1482</ispartof><rights>2024. The Author(s).</rights><rights>COPYRIGHT 2024 BioMed Central Ltd.</rights><rights>2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c445t-70010c6d21ab326fc502070d7297a6d28b16d47b938c69b7b2ffbfd566a75da63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11145832/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3066885277?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25732,27903,27904,36991,36992,38495,43874,44569,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38831285$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mazhnaya, Alyona</creatorcontrib><creatorcontrib>Geurts, Brogan</creatorcontrib><creatorcontrib>Brigida, Krestina</creatorcontrib><creatorcontrib>Bakieva, Shokhista</creatorcontrib><creatorcontrib>Sadirova, Shakhlo</creatorcontrib><creatorcontrib>Witzigmann, Annika</creatorcontrib><creatorcontrib>Musabaev, Erkin</creatorcontrib><creatorcontrib>Brandl, Michael</creatorcontrib><creatorcontrib>Weishaar, Heide</creatorcontrib><creatorcontrib>Dudareva, Sandra</creatorcontrib><creatorcontrib>Bcheraoui, Charbel El</creatorcontrib><title>Barriers and facilitators to viral hepatitis testing in Uzbekistan: scoping qualitative study among key stakeholders, healthcare workers, and the general population</title><title>BMC public health</title><addtitle>BMC Public Health</addtitle><description>In the World Health Organization European Region, an estimated 14 million people live with a chronic hepatitis B virus infection (HBV), and 12 million are affected by a hepatitis C virus infection (HCV). Uzbekistan bears a major burden of HBV and has one of the highest HCV prevalence in the region. Following a presidential decree in May 2022, significant funds were allocated to the viral hepatitis (VH) elimination program in Uzbekistan. The program expands VH testing to reach 500,000 people annually during 2022-2025 as part of the VH elimination strategy that includes the provision of free testing and affordable treatment. Exploring the existing barriers and facilitators to VH testing is pivotal for informing these interventions.
This study uses a cross-sectional qualitative design to identify and explore the barriers and facilitators to VH testing among the general population in Uzbekistan. We collected data during October-November 2022 through semi-structured interviews with 12 key informants (KIs) and 7 focus group discussions with two target populations: the general population and healthcare workers (HCW) in Tashkent, Uzbekistan.
Following the capability-opportunity-motivation-behavior model (COM-B model) as a framework for the analysis, we identified major capability barriers to VH testing primarily linked to low health literacy and limited knowledge about VH types, symptoms, transmission, testing and treatment. Physical opportunity barriers included the time and financial costs associated with testing, diagnostics, and treatment. Sociocultural opportunity barriers involved anticipated negative reactions and stigmatization, particularly affecting women. Motivational barriers included a reluctance to be tested when asymptomatic and a general fear of receiving positive test results. The involvement of healthcare workers in promoting VH awareness and motivating the general population emerged as a facilitator.
A multi-pronged approach is recommended to achieve VH testing goals among the general population, focusing on raising awareness and health literacy and creating an enabling environment that ensures easy accessibility and minimizing VH testing-associated costs.</description><subject>Adult</subject><subject>Barriers and facilitators</subject><subject>Behavior change</subject><subject>Care and treatment</subject><subject>Central Asia</subject><subject>Chronic illnesses</subject><subject>Chronic infection</subject><subject>Cross-Sectional Studies</subject><subject>Diagnosis</subject><subject>Disease transmission</subject><subject>Elimination</subject><subject>Female</subject><subject>Females</subject><subject>Focus Groups</subject><subject>Health behavior</subject><subject>Health care</subject><subject>Health Personnel - psychology</subject><subject>Health Services Accessibility</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis C</subject><subject>Hepatitis testing</subject><subject>Hepatitis, Viral</subject><subject>Hepatitis, Viral, Human - diagnosis</subject><subject>Hepatitis, Viral, Human - epidemiology</subject><subject>Hepatitis, Viral, Human - prevention & control</subject><subject>Humans</subject><subject>Immunization</subject><subject>Infections</subject><subject>Interviews as Topic</subject><subject>Literacy</subject><subject>Male</subject><subject>Mass Screening</subject><subject>Medical personnel</subject><subject>Middle Aged</subject><subject>Pilot projects</subject><subject>Population</subject><subject>Practice</subject><subject>Prevention</subject><subject>Primary care</subject><subject>Public health</subject><subject>Qualitative Research</subject><subject>Risk factors</subject><subject>Stakeholder Participation</subject><subject>Uzbekistan</subject><issn>1471-2458</issn><issn>1471-2458</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptks9u1DAQxiMEoqXwAhxQJC4cSLEdJ3a4oFLxp1IlLvRsTRx717vZOLWdRcvz8KBMdkvpIpRDki_z_SYz_rLsJSXnlMr6XaRMyqYgjBdUNlVZVI-yU8oFLRiv5OMHzyfZsxhXhFAhK_Y0OymlLNFcnWa_PkIIzoSYw9DlFrTrXYLkUUg-37oAfb40IySXHEomJjcscjfkNz9bs3YxwfA-j9qPs3w7wd7ttiaPaep2OWw86muzw3dYm6XvO-z1FpHQp6WGYPIfPqz32vwDaWnyhRnM3Hb049QjzA_PsycW-mhe3N3PspvPn75ffi2uv325ury4LjTnVSoEDkh03TEKbclqqyvCiCCdYI0AlGVL646LtimlrptWtMza1nZVXYOoOqjLs-zqwO08rNQY3AbCTnlwai_4sFAQktO9UVZbKQThHDRwwhvZ0LatrBWAjWXTIuvDgTVO7cZ02gwJhzqCHn8Z3FIt_FZRSvHESoaEN3eE4G8n3LzauKhN38Ng_BRVSWpeiaYhHEtf_1O68lMYcFdzVS3x1IX4W7UAnMAN1mNjPUPVhWhqVpaCz6zz_1Th1ZmN034w1qF-ZGAHgw4-xmDs_ZCUqDmo6hBUhUFV-6CqCk2vHq7n3vInmeVvJOPmuA</recordid><startdate>20240603</startdate><enddate>20240603</enddate><creator>Mazhnaya, Alyona</creator><creator>Geurts, Brogan</creator><creator>Brigida, Krestina</creator><creator>Bakieva, Shokhista</creator><creator>Sadirova, Shakhlo</creator><creator>Witzigmann, Annika</creator><creator>Musabaev, Erkin</creator><creator>Brandl, Michael</creator><creator>Weishaar, Heide</creator><creator>Dudareva, Sandra</creator><creator>Bcheraoui, Charbel El</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FE</scope><scope>8FG</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>L6V</scope><scope>M0S</scope><scope>M1P</scope><scope>M7S</scope><scope>PATMY</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20240603</creationdate><title>Barriers and facilitators to viral hepatitis testing in Uzbekistan: scoping qualitative study among key stakeholders, healthcare workers, and the general population</title><author>Mazhnaya, Alyona ; Geurts, Brogan ; Brigida, Krestina ; Bakieva, Shokhista ; Sadirova, Shakhlo ; Witzigmann, Annika ; Musabaev, Erkin ; Brandl, Michael ; Weishaar, Heide ; Dudareva, Sandra ; Bcheraoui, Charbel El</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c445t-70010c6d21ab326fc502070d7297a6d28b16d47b938c69b7b2ffbfd566a75da63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Barriers and facilitators</topic><topic>Behavior change</topic><topic>Care and treatment</topic><topic>Central Asia</topic><topic>Chronic illnesses</topic><topic>Chronic infection</topic><topic>Cross-Sectional Studies</topic><topic>Diagnosis</topic><topic>Disease transmission</topic><topic>Elimination</topic><topic>Female</topic><topic>Females</topic><topic>Focus Groups</topic><topic>Health behavior</topic><topic>Health care</topic><topic>Health Personnel - psychology</topic><topic>Health Services Accessibility</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis C</topic><topic>Hepatitis testing</topic><topic>Hepatitis, Viral</topic><topic>Hepatitis, Viral, Human - diagnosis</topic><topic>Hepatitis, Viral, Human - epidemiology</topic><topic>Hepatitis, Viral, Human - prevention & control</topic><topic>Humans</topic><topic>Immunization</topic><topic>Infections</topic><topic>Interviews as Topic</topic><topic>Literacy</topic><topic>Male</topic><topic>Mass Screening</topic><topic>Medical personnel</topic><topic>Middle Aged</topic><topic>Pilot projects</topic><topic>Population</topic><topic>Practice</topic><topic>Prevention</topic><topic>Primary care</topic><topic>Public health</topic><topic>Qualitative Research</topic><topic>Risk factors</topic><topic>Stakeholder Participation</topic><topic>Uzbekistan</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mazhnaya, Alyona</creatorcontrib><creatorcontrib>Geurts, Brogan</creatorcontrib><creatorcontrib>Brigida, Krestina</creatorcontrib><creatorcontrib>Bakieva, Shokhista</creatorcontrib><creatorcontrib>Sadirova, Shakhlo</creatorcontrib><creatorcontrib>Witzigmann, Annika</creatorcontrib><creatorcontrib>Musabaev, Erkin</creatorcontrib><creatorcontrib>Brandl, Michael</creatorcontrib><creatorcontrib>Weishaar, Heide</creatorcontrib><creatorcontrib>Dudareva, Sandra</creatorcontrib><creatorcontrib>Bcheraoui, Charbel El</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Engineering Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Engineering Database</collection><collection>Environmental Science Database</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering collection</collection><collection>Environmental Science Collection</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>BMC public health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mazhnaya, Alyona</au><au>Geurts, Brogan</au><au>Brigida, Krestina</au><au>Bakieva, Shokhista</au><au>Sadirova, Shakhlo</au><au>Witzigmann, Annika</au><au>Musabaev, Erkin</au><au>Brandl, Michael</au><au>Weishaar, Heide</au><au>Dudareva, Sandra</au><au>Bcheraoui, Charbel El</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Barriers and facilitators to viral hepatitis testing in Uzbekistan: scoping qualitative study among key stakeholders, healthcare workers, and the general population</atitle><jtitle>BMC public health</jtitle><addtitle>BMC Public Health</addtitle><date>2024-06-03</date><risdate>2024</risdate><volume>24</volume><issue>1</issue><spage>1482</spage><epage>1482</epage><pages>1482-1482</pages><artnum>1482</artnum><issn>1471-2458</issn><eissn>1471-2458</eissn><abstract>In the World Health Organization European Region, an estimated 14 million people live with a chronic hepatitis B virus infection (HBV), and 12 million are affected by a hepatitis C virus infection (HCV). Uzbekistan bears a major burden of HBV and has one of the highest HCV prevalence in the region. Following a presidential decree in May 2022, significant funds were allocated to the viral hepatitis (VH) elimination program in Uzbekistan. The program expands VH testing to reach 500,000 people annually during 2022-2025 as part of the VH elimination strategy that includes the provision of free testing and affordable treatment. Exploring the existing barriers and facilitators to VH testing is pivotal for informing these interventions.
This study uses a cross-sectional qualitative design to identify and explore the barriers and facilitators to VH testing among the general population in Uzbekistan. We collected data during October-November 2022 through semi-structured interviews with 12 key informants (KIs) and 7 focus group discussions with two target populations: the general population and healthcare workers (HCW) in Tashkent, Uzbekistan.
Following the capability-opportunity-motivation-behavior model (COM-B model) as a framework for the analysis, we identified major capability barriers to VH testing primarily linked to low health literacy and limited knowledge about VH types, symptoms, transmission, testing and treatment. Physical opportunity barriers included the time and financial costs associated with testing, diagnostics, and treatment. Sociocultural opportunity barriers involved anticipated negative reactions and stigmatization, particularly affecting women. Motivational barriers included a reluctance to be tested when asymptomatic and a general fear of receiving positive test results. The involvement of healthcare workers in promoting VH awareness and motivating the general population emerged as a facilitator.
A multi-pronged approach is recommended to achieve VH testing goals among the general population, focusing on raising awareness and health literacy and creating an enabling environment that ensures easy accessibility and minimizing VH testing-associated costs.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>38831285</pmid><doi>10.1186/s12889-024-18953-5</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1471-2458 |
ispartof | BMC public health, 2024-06, Vol.24 (1), p.1482-1482, Article 1482 |
issn | 1471-2458 1471-2458 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_fcf877044aca4049891bb5ff7a26f89b |
source | PMC (PubMed Central); Publicly Available Content (ProQuest); Coronavirus Research Database |
subjects | Adult Barriers and facilitators Behavior change Care and treatment Central Asia Chronic illnesses Chronic infection Cross-Sectional Studies Diagnosis Disease transmission Elimination Female Females Focus Groups Health behavior Health care Health Personnel - psychology Health Services Accessibility Hepatitis Hepatitis B Hepatitis C Hepatitis testing Hepatitis, Viral Hepatitis, Viral, Human - diagnosis Hepatitis, Viral, Human - epidemiology Hepatitis, Viral, Human - prevention & control Humans Immunization Infections Interviews as Topic Literacy Male Mass Screening Medical personnel Middle Aged Pilot projects Population Practice Prevention Primary care Public health Qualitative Research Risk factors Stakeholder Participation Uzbekistan |
title | Barriers and facilitators to viral hepatitis testing in Uzbekistan: scoping qualitative study among key stakeholders, healthcare workers, and the general population |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T03%3A03%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Barriers%20and%20facilitators%20to%20viral%20hepatitis%20testing%20in%20Uzbekistan:%20scoping%20qualitative%20study%20among%20key%20stakeholders,%20healthcare%20workers,%20and%20the%20general%20population&rft.jtitle=BMC%20public%20health&rft.au=Mazhnaya,%20Alyona&rft.date=2024-06-03&rft.volume=24&rft.issue=1&rft.spage=1482&rft.epage=1482&rft.pages=1482-1482&rft.artnum=1482&rft.issn=1471-2458&rft.eissn=1471-2458&rft_id=info:doi/10.1186/s12889-024-18953-5&rft_dat=%3Cgale_doaj_%3EA796233744%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c445t-70010c6d21ab326fc502070d7297a6d28b16d47b938c69b7b2ffbfd566a75da63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3066885277&rft_id=info:pmid/38831285&rft_galeid=A796233744&rfr_iscdi=true |